Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Onconetix (ONCO) EBIT (2023 - 2025)

Historic EBIT for Onconetix (ONCO) over the last 3 years, with Q3 2025 value amounting to -$2.1 million.

  • Onconetix's EBIT rose 2179.34% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.7 million, marking a year-over-year increase of 743.08%. This contributed to the annual value of -$56.5 million for FY2024, which is 5676.26% down from last year.
  • Onconetix's EBIT amounted to -$2.1 million in Q3 2025, which was up 2179.34% from -$1.9 million recorded in Q2 2025.
  • In the past 5 years, Onconetix's EBIT registered a high of -$1.9 million during Q2 2025, and its lowest value of -$29.1 million during Q4 2024.
  • For the 3-year period, Onconetix's EBIT averaged around -$9.9 million, with its median value being -$6.6 million (2023).
  • Per our database at Business Quant, Onconetix's EBIT crashed by 28907.94% in 2024 and then soared by 8578.47% in 2025.
  • Quarter analysis of 3 years shows Onconetix's EBIT stood at -$22.0 million in 2023, then crashed by 32.19% to -$29.1 million in 2024, then surged by 92.9% to -$2.1 million in 2025.
  • Its EBIT was -$2.1 million in Q3 2025, compared to -$1.9 million in Q2 2025 and -$12.6 million in Q1 2025.